Lopinavir News and Research

RSS
New trial examines use of nanotechnology to improve delivery of drugs to HIV patients

New trial examines use of nanotechnology to improve delivery of drugs to HIV patients

New study proves that 'super-boosting' approach may help treat children co-infected with TB and HIV

New study proves that 'super-boosting' approach may help treat children co-infected with TB and HIV

New research examines use of nanotechnology to improve delivery of drugs to HIV patients

New research examines use of nanotechnology to improve delivery of drugs to HIV patients

Hitchhiking of drugs on incorrect targets can cause adverse side effects

Hitchhiking of drugs on incorrect targets can cause adverse side effects

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

MPP signs licensing agreement with AbbVie to address future demands for HIV treatment in Africa

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

MPP collaborates with University of Liverpool to accelerate development of HIV nanomedicines

MPP collaborates with University of Liverpool to accelerate development of HIV nanomedicines

12 months of liquid formula HIV drugs protect breastfeeding babies against HIV infection

12 months of liquid formula HIV drugs protect breastfeeding babies against HIV infection

Study evaluates effectiveness of antiretroviral treatment in HIV-infected children

Study evaluates effectiveness of antiretroviral treatment in HIV-infected children

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

Janssen announces availability of PREZCOBIX for Canadians living with HIV

Janssen announces availability of PREZCOBIX for Canadians living with HIV

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

New study explores the effect of food insecurity on treating HIV-infected pregnant women in Uganda

New study explores the effect of food insecurity on treating HIV-infected pregnant women in Uganda

Commonly-used HIV drug kills HPV that leads to cervical cancer

Commonly-used HIV drug kills HPV that leads to cervical cancer